Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

Summary

This pilot trial studies how well leflunomide works for the treatment of patients with high-risk smoldering plasma cell myeloma, for the delay of disease progression. Anti-inflammatory drugs, such as leflunomide lower the body's immune response and are used with other drugs in the treatment of some types of cancer. The information learned from this study will help researchers to learn more about the anti-myeloma activity of leflunomide, and whether it may delay the onset of symptomatic multiple myeloma in patients with high-risk smoldering multiple myeloma.

Timeline

Start

2020-10-08

Primary completion

2026-11-10

Completion

2026-11-10

Drugs

Indications